Chen Shi-Qi, Gou Rui-Qin, Zhang Qing
Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang City, Jiangxi Province, China.
Nucl Med Commun. 2025 Mar 1;46(3):204-217. doi: 10.1097/MNM.0000000000001940. Epub 2024 Dec 6.
Hyperthyroidism, a prevalent endocrine disorder, disrupts metabolic balance and cardiovascular health, affecting millions globally. Radioactive iodine (RAI), a treatment for hyperthyroidism, employs high-energy beta particles to reduce thyroid tissue, lowering volume and hormone levels. This study utilizes bibliometric analysis to outline RAI's evolution and identify hotspots in hyperthyroidism treatment.
A total of 2904 articles and reviews published between 1981 and 2023 were retrieved from the Web of Science Core Collection using the research strategy. Bibliometric analyses, employing VOSviewer and CiteSpace, were performed to visualize the cooperation network, evolution, and hot topics.
Annual publications rose in waves, 2904 papers from 2564 institutions, and 84 countries. The USA led, contributing the largest share, with the journal Thyroid dominating publication. The University of Pisa contributed the most articles. Co-occurrence analysis classified keywords into five clusters: treatment mechanism, safety, effectiveness assessment, individualized radioactive dosage, and management. The development of RAI therapy for hyperthyroidism can be divided into three stages: safety and efficacy assessment, personalized treatment plans, and treatment of drug-resistant and surgery-resistant hyperthyroidism.
Attention to RAI in hyperthyroidism should be significantly increased. It is necessary to establish collaborations between authors, countries, and institutions to promote the development of this field. Recent research has focused on personalized radioactive dosage formulation and follow-up. Future studies are likely to concentrate on drug-resistant and surgery-resistant hyperthyroidism, which is also worthy of investigation. These findings provide a new perspective on the study of RAI in hyperthyroidism, potentially contributing to the improvement of the quality of life for patients with hyperthyroidism.
甲状腺功能亢进症是一种常见的内分泌疾病，会破坏代谢平衡和心血管健康，全球数百万人受其影响。放射性碘（RAI）是一种治疗甲状腺功能亢进症的方法，利用高能β粒子减少甲状腺组织，降低其体积和激素水平。本研究利用文献计量分析概述RAI的发展历程，并确定甲状腺功能亢进症治疗的热点。
使用该研究策略从科学网核心合集中检索了1981年至2023年发表的2904篇文章和综述。采用VOSviewer和CiteSpace进行文献计量分析，以可视化合作网络、发展历程和热点话题。
年度出版物呈波浪式增长，来自2564个机构和84个国家的2904篇论文。美国领先，贡献份额最大，《甲状腺》杂志主导了出版物。比萨大学贡献的文章最多。共现分析将关键词分为五个聚类：治疗机制、安全性、疗效评估、个体化放射性剂量和管理。RAI治疗甲状腺功能亢进症的发展可分为三个阶段：安全性和疗效评估、个性化治疗方案以及耐药和手术难治性甲状腺功能亢进症的治疗。
应显著提高对甲状腺功能亢进症中RAI的关注度。有必要在作者、国家和机构之间建立合作，以促进该领域的发展。最近的研究集中在个性化放射性剂量配方和随访上。未来的研究可能会集中在耐药和手术难治性甲状腺功能亢进症上，这也值得研究。这些发现为甲状腺功能亢进症中RAI的研究提供了新的视角，可能有助于提高甲状腺功能亢进症患者的生活质量。
